Article metrics

Download PDFPDF

Original article
Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

 

Online download statistics by month:

Online download statistics by month: March 2019 to April 2024

AbstractFullPdf
Mar 2019615830
Apr 2019237231117
May 201931630680
Jun 201916515841
Jul 2019959725
Aug 2019717027
Sep 2019656125
Oct 2019929128
Nov 201911111156
Dec 201911911717
Jan 202011411124
Feb 2020717116
Mar 2020565522
Apr 2020343319
May 2020727226
Jun 2020363625
Jul 2020454011
Aug 2020333030
Sep 2020575038
Oct 2020565422
Nov 2020514518
Dec 2020393114
Jan 202142328
Feb 202142318
Mar 2021403319
Apr 2021663221
May 2021332411
Jun 2021555112
Jul 202127239
Aug 2021373513
Sep 2021211910
Oct 2021242331
Nov 2021232216
Dec 2021312510
Jan 2022313219
Feb 2022354014
Mar 2022303113
Apr 2022494814
May 2022464213
Jun 2022413918
Jul 202226259
Aug 202250499
Sep 2022454522
Oct 2022444720
Nov 2022202012
Dec 202218177
Jan 202315165
Feb 2023333310
Mar 202317177
Apr 2023262321
May 2023221822
Jun 2023141313
Jul 2023171611
Aug 2023558
Sep 20231088
Oct 2023231910
Nov 202324218
Dec 2023292912
Jan 2024221913
Feb 2024191314
Mar 2024333226
Apr 2024323020
Total321330251257